We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
News

Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory

Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
News

Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pharmatek Laboratories, Inc. has announced the addition of cytotoxic and high-potent drug development capabilities to its pharmaceutical chemistry development services.

Cytotoxic and high-potent services include analytical method development, preformulation testing, formulation development, manufacturing for early phase clinical trials, release testing, and stability testing and storage.

“This expansion was driven by an increase in demand for cytotoxic and high-potent drug development and manufacturing outsourcing among our clients,” said Dr. Jeffrey Bibbs, CEO of Pharmatek. “This added capability enables us to provide a broader level of services to our clients with cytotoxic and high-potent candidates.”

Pharmatek’s cytotoxic and high-potent development services will be carried out in a separate dedicated facility. Manufacturing capability includes two validated and licensed class 100,000 high-containment suites designed with barrier technology for cGMP manufacturing of final form drug products.

Dedicated HVAC and HEPA filtration systems ensure product containment within the suites. Personnel are protected through strict gowning and control procedures to ensure employee safety while working in the suites.

“Pharmatek has been a valued resource for the development and manufacturing of non-potent drugs for more than eight years,” said Timothy Scott, president of Pharmatek. “This investment positions Pharmatek to become a leading cytotoxic and high-potent drug development service provider.”

Advertisement